← Back to Search

Small Molecule

ATH434 for Multiple System Atrophy

Phase 2
Waitlist Available
Research Sponsored by Alterity Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participant has evidence of orthostatic hypotension and/or bladder dysfunction.
Participant has clinical features of parkinsonism.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline to week 52
Awards & highlights

Study Summary

This trial will test a new drug to see if it is safe and effective for people with Multiple System Atrophy.

Who is the study for?
This trial is for individuals with Multiple System Atrophy (MSA), showing symptoms like parkinsonism, low blood pressure upon standing, bladder issues, ataxia or abnormal muscle coordination, and certain signs on a neurological exam. They must have MSA biomarkers in their body fluids and MRI scans. People can't join if they can't swallow pills, attend visits, have brain structure issues on MRI, unstable health conditions or other significant neurological disorders.Check my eligibility
What is being tested?
The study is testing the safety and effectiveness of a drug called ATH434 in people who are clinically diagnosed with Multiple System Atrophy. It aims to see how well this drug works and what effects it has on patients' bodies.See study design
What are the potential side effects?
While the specific side effects of ATH434 aren't listed here, common types of side effects from drugs treating similar conditions may include nausea, dizziness due to low blood pressure (especially when getting up), digestive problems or allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I experience dizziness when standing up or have bladder control issues.
Select...
I show symptoms similar to Parkinson's disease.
Select...
I have coordination issues or muscle weakness.
Select...
My tests show MSA markers in my body fluids and on my MRI.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline to week 52
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline to week 52 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in iron content as measured by brain MRI
Secondary outcome measures
Change in 36-Item Short Form Survey (SF-36) Score
Change in Aggregating alpha-Synuclein Levels
Change in Neurofilament Light Chain Levels
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: ATH434Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Alterity TherapeuticsLead Sponsor
2 Previous Clinical Trials
92 Total Patients Enrolled
2 Trials studying Multiple System Atrophy
92 Patients Enrolled for Multiple System Atrophy

Media Library

ATH434 (Small Molecule) Clinical Trial Eligibility Overview. Trial Name: NCT05864365 — Phase 2
Multiple System Atrophy Research Study Groups: ATH434
Multiple System Atrophy Clinical Trial 2023: ATH434 Highlights & Side Effects. Trial Name: NCT05864365 — Phase 2
ATH434 (Small Molecule) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05864365 — Phase 2
Multiple System Atrophy Patient Testimony for trial: Trial Name: NCT05864365 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are elderly individuals aged 75 or above permitted to enter into this research?

"This medical trial is available to those aged 30 or more and below 75 years of age."

Answered by AI

Do I satisfy the eligibility criteria to partake in this investigation?

"To be considered for this trial, individuals must have a diagnosis of multiple system atrophy and fall within the age range from 30 to 75. This study aims to recruit 15 qualified volunteers in total."

Answered by AI

Is this research project currently seeking participants?

"Affirmative. According to the data found on clinicaltrials.gov, this research endeavour is currently looking for enrollees. The experiment was listed on May 1st 2023 and revised a week later on May 9th 2023, with an aim of recruiting 15 participants from one site."

Answered by AI

How many participants have registered for this clinical exploration?

"Affirmative, the clinicaltrials.gov website suggests that this trial is open for recruitment at present. This research endeavor was initially published on May 1st 2023 and has been updated as of May 9th 2023. 15 participants are being sought from a single medical site."

Answered by AI

What risk factors might be associated with taking ATH434?

"ATH434 has accrued some safety data, prompting our team to rate it a 2. This is reflective of the fact that we are currently in Phase two trials and have yet to determine efficacy."

Answered by AI

Who else is applying?

What state do they live in?
Virginia
North Carolina
Oklahoma
What site did they apply to?
Vanderbilt University Medical Center
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
0
1

What questions have other patients asked about this trial?

How often do we need to present for medication or testing? Possible side effects?
PatientReceived 1 prior treatment

Why did patients apply to this trial?

I'm hoping to find a cure. I am a single mother with 2 chikdrenl. MSA is a horrible disease. I want to help contribute to the research and help other people.
PatientReceived 1 prior treatment
My Movement Disorder Specialist was promoted to Head of Neurology and no longer sees patients. I believe there is something out there undiscovered that can help or cure MSA. I want my life back.
PatientReceived no prior treatments

How responsive is this trial?

Typically responds via
Phone Call
Email
Most responsive sites:
  1. Vanderbilt University Medical Center: < 48 hours
Average response time
  • < 2 Days
Recent research and studies
clinicaltrials.govStudy
Biomarker Study of ATH434 in Participants With MSA
2023. "Biomarker Study of ATH434 in Participants With MSA". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05864365.
All > Multiple System Atrophy
~7 spots leftby Feb 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top